{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:34:43Z","timestamp":1762544083715,"version":"3.37.0"},"reference-count":30,"publisher":"Baishideng Publishing Group Inc.","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Clin Cases"],"abstract":"<jats:p>BACKGROUND<\/jats:p>\n          <jats:p>Pancreatic cancer (PC) is a highly malignant tumor that is resistant to chemotherapy, radiotherapy and immunotherapy. Combination chemotherapy regimens are the standard first-line regimens for metastatic disease, with a median survival &lt; 12 months. Although recurrent genomic alterations such as the BRAF  V600E mutation have been reported in PC, evidence supporting the clinical effectiveness of molecularly guided targeted therapies is limited.<\/jats:p>\n          <jats:p>CASE SUMMARY<\/jats:p>\n          <jats:p>We report a case of a 33-year-old male who was referred to our department with weight loss of 5 kg in 2 months, anorexia and abdominal pain. Imaging showed extensive lesions involving the pancreas, liver, bones, muscles and lymph nodes accompanied by elevated carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA). Biopsy yielded a diagnosis of PC. Treatment with gemcitabine and nab-paclitaxel was initiated, but the disease progressed in &lt; 2 months even though the patient\u2019s general condition improved. Molecular testing revealed the presence of BRAF  mutation. Dabrafenib\/trametinib combination therapy was introduced, and the patient was treated for 2 months with a decrease in CA19-9 and CEA levels, but he died after 2 months of treatment.<\/jats:p>\n          <jats:p>CONCLUSION<\/jats:p>\n          <jats:p>BRAF  alterations are infrequent in PC. This case highlights the significance of molecular profiling in patients with PC, especially in patients with a high tumor burden.<\/jats:p>","DOI":"10.12998\/wjcc.v13.i16.101665","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T03:43:21Z","timestamp":1739159001000},"source":"Crossref","is-referenced-by-count":1,"title":["Metastatic pancreatic cancer with activating <i>BRAF<\/i> V600E mutations: A case report"],"prefix":"10.12998","volume":"13","author":[{"given":"Fang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/path.5260"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ags3.12311"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30416-9"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.01.259"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2019.02.025"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00457-x"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00986-1"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3099"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.02.037"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7641"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903387"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7744"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30074-7"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00762"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0017"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3179755\/v1"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1502309"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.3780"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.36.4_suppl.214"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00494"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a006108"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00343"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1159\/000510096"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1159\/000496018"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-22-0626"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174400"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-031621-024600"}],"container-title":["World Journal of Clinical Cases"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v13\/i16\/101665.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v13\/i16\/101665.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T03:43:34Z","timestamp":1739159014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v13\/i16\/101665.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":30,"journal-issue":{"issue":"16"},"alternative-id":["101665"],"URL":"https:\/\/doi.org\/10.12998\/wjcc.v13.i16.101665","relation":{},"ISSN":["2307-8960"],"issn-type":[{"value":"2307-8960","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,6]]}}}